Last reviewed · How we verify

NCT05093400

Oropharynx (OPX) Salivary Biomarker Study

Completed Last updated 7 July 2023
What this trial tests

trial testing no intervention in Healthy in 100 participants. Completed in 5 May 2023.

Timeline
17 September 2021
Primary endpoint
2 May 2023
5 May 2023

Quick facts

Lead sponsorMayo Clinic
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date17 September 2021
Primary completion2 May 2023
Estimated completion5 May 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

Adults 18 to 100, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to analyze certain biomarkers to look at the relationship between HPV in the saliva, stage at presentation, and a potential self-test compared to saliva of non-cancerous participants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Advancements and Challenges in Salivary Metabolomics for Early Detection and Monitoring of Systemic Diseases.
    Zhao X, Chen X, Zhou Z, Zheng J, et al · · 2025 · cited 1× · PMID 40989572 · DOI 10.1002/mco2.70395

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05093400.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing